-

Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is proud to announce that it has received a sustainability Gold Medal from EcoVadis, placing the contract research organization (CRO) in the 96th percentile and among the top 5% of companies evaluated globally. EcoVadis, the world’s most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company’s commitment to a sustainable future and a reduced environmental footprint.

Altasciences is proud to announce that it has received a sustainability Gold Medal from EcoVadis, placing the contract research organization (CRO) in the 96th percentile and among the top 5% of companies evaluated globally.

Share

Supported by a powerful technology platform and a team of experts, EcoVadis rated Altasciences on several criteria: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement—all of which achieved scores above 75 out of 100. “We have made great strides in our ESG initiatives, and these scores demonstrate our team's hard work and commitment to ESG principles and a sustainable future,” said David Grégoire, Chief Quality and Compliance Officer, Altasciences.

With responsibility at the heart of its values, Altasciences has integrated ESG principles into every aspect of its operations, championing sustainable practices, ethical governance, inclusion, and employee well-being, and has increased its sustainability rating by 30% from 2024 to 2025.

As a committed participant in the UN Global Compact, the company upholds principles of human rights, labor standards, environmental stewardship and anti-corruption, and is advancing toward science-based emission reductions by 2030, in alignment with the Science Based Targets initiative (SBTi).

For more information on Altasciences’ commitment to ESG and sustainability efforts, visit the company website.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.

Contacts

Julie-Ann Cabana
Altasciences
media@altasciences.com

More News From Altasciences

Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulat...

Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud t...

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. This partnership combines Altasciences’ comprehensive early-phase drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to of...
Back to Newsroom